DDReg Pharma

DELIVER BETTER DATA TO ENSURE FASTER APPROVAL

Regulatory

Mitigating medical device shortages in public health emergencies

The onset of the pandemic amplified an already growing concern in the European Union (EU)- the shortage of medicines, equipment, and devices that subsequently burdens the health system and puts patients at risk. Some of the reasons for these kinds of shortages are related to problems in manufacturing that can delay production, shortages of raw …

Mitigating medical device shortages in public health emergencies Read More »

Digitalization in Regulatory Affairs

Technology is rapidly driving the growth of the Pharmaceutical and Life Sciences industries. With digital solutions being made more easily available, drug development & pharmacovigilance are transforming to become more efficient, compliant, and patient safety focused. However, regulatory affairs is still somewhat manual where processes and tasks are repetitive, siloed, and resource-heavy. Though Life Sciences …

Digitalization in Regulatory Affairs Read More »

Convergence of regulatory frameworks surrounding cell, tissue, and gene therapy products

Cell, tissue, or gene therapy products (CTGTPs) can contain non-viable or viable human cells or tissues, viable animal cells or tissues, or recombinant nucleic acids and are intended for use in humans to treat, prevent, or even diagnosis conditions that are associated with high treatment burden [1]. However, regulations surrounding CTGTPs vary per region as …

Convergence of regulatory frameworks surrounding cell, tissue, and gene therapy products Read More »

The impact of the Russia-Ukraine war on clinical trials

The Russia-Ukraine war has undoubtedly affected millions of people in and around the world. Several industries have taken a huge hit where operational and business continuity has been threatened, pharmaceutical industry being one of them. From the delays along the drug development pipeline, to non-compliance products in the market being at risk, the industry faces …

The impact of the Russia-Ukraine war on clinical trials Read More »

DDReg’s RegTech space: your regulatory solution for achieving rapid market access

RegTech focuses on technologies that may facilitate the delivery of regulatory requirements more efficiently and effectively than existing capabilities. The global adoption of RegTech is a result of increased regulatory scrutiny, compliance costs, development of artificial intelligence, evolution of data science and increasing demands regarding cost-effective compliance solutions. With ever changing regulatory requirements, pharmaceutical organizations …

DDReg’s RegTech space: your regulatory solution for achieving rapid market access Read More »

Biologics development & regulatory approval – EMA perspective

Biologic medicinal products, particularly biosimilars, have revolutionized the treatment of chronic conditions. As biologic products lose patent protection, biosimilars emerge as more readily accessible treatment alternatives. In the European Union (EU), the European Medicines Agency (EMA) is responsible for product approval. The EMA was the first regulatory authority to establish a regulatory framework for biosimilars …

Biologics development & regulatory approval – EMA perspective Read More »

Biosimilarity and Interchangeability in the MENA region

A biological drug (or biologic) is one that is produced from a living organism or contains components of a living organism. They have become indispensable tools in modern medicine, for treatment of life-threatening conditions. With an aging population and a growing demand for treating chronic conditions, biologic use is on the rise. However, they are …

Biosimilarity and Interchangeability in the MENA region Read More »

Knowledge Management in Regulatory Affairs (KMRA)

Knowledge management (KM) has been a recognized discipline in other sectors for over 20 years, but it has taken a long time for the biopharmaceutical business to debate and formalize it. When the ICH guideline paper Pharmaceutical Quality System: Q10 was published in 2008, it highlighted knowledge management as a major enabler of a pharmaceutical …

Knowledge Management in Regulatory Affairs (KMRA) Read More »